Trial Profile
Prognostic evaluation with focus on renal function of molecular target drugs for Unresectable or Metastatic Renal Cell Carcinoma patients with Renal Dysfunction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 20 Oct 2017 Status changed from recruiting to discontinued.
- 17 May 2016 New trial record